PMID- 31526779
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20240427
IS  - 1552-6259 (Electronic)
IS  - 0003-4975 (Print)
IS  - 0003-4975 (Linking)
VI  - 109
IP  - 4
DP  - 2020 Apr
TI  - Intramyocardial Bone Marrow Stem Cells in Patients Undergoing Cardiac Surgical 
      Revascularization.
PG  - 1142-1149
LID - S0003-4975(19)31394-3 [pii]
LID - 10.1016/j.athoracsur.2019.07.093 [doi]
AB  - BACKGROUND: Bone marrow stromal or stem cells (BMSCs) remain a promising 
      potential therapy for ischemic cardiomyopathy. The primary objective of this 
      study was to evaluate the safety and feasibility of direct intramyocardial 
      injection of autologous BMSCs in patients undergoing transmyocardial 
      revascularization (TMR) or coronary artery bypass graft surgery (CABG). METHODS: 
      A phase I trial was conducted on adult patients who had ischemic heart disease 
      with depressed left ventricular ejection fraction and who were scheduled to 
      undergo TMR or CABG. Autologous BMSCs were expanded for 3 weeks before the 
      scheduled surgery. After completion of surgical revascularization, BMSCs were 
      directly injected into ischemic myocardium. Safety and feasibility of therapy 
      were assessed. Cardiac functional status and changes in quality of life were 
      evaluated at 1 year. RESULTS: A total of 14 patients underwent simultaneous BMSC 
      and surgical revascularization therapy (TMR+BMSCs = 10; CABG+BMSCs = 4). BMSCs 
      were successfully expanded, and no significant complications occurred as a result 
      of the procedure. Regional contractility in the cell-treated areas demonstrated 
      improvement at 12 months compared with baseline (TMR+BMSCs Delta strain: -4.6% +/- 
      2.1%; P = .02; CABG+MSCs Delta strain: -4.2% +/- 6.0%; P = .30). Quality of life was 
      enhanced, with substantial reduction in angina scores at 1 year after treatment 
      (TMR+BMSCs: 1.3 +/- 1.2; CABG+MSCs: 1.0 +/- 1.4). CONCLUSIONS: In this phase I trial, 
      direct intramyocardial injection of autologous BMSCs in conjunction with TMR or 
      CABG was technically feasible and could be performed safely. Preliminary results 
      demonstrate improved cardiac function and quality of life in patients at 1 year 
      after treatment.
CI  - Copyright (c) 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All 
      rights reserved.
FAU - Chan, Joshua L
AU  - Chan JL
AD  - Cardiothoracic Surgery Research Program, National Heart, Lung and Blood 
      Institute, National Institutes of Health, Bethesda, Maryland.
FAU - Miller, Justin G
AU  - Miller JG
AD  - Cardiothoracic Surgery Research Program, National Heart, Lung and Blood 
      Institute, National Institutes of Health, Bethesda, Maryland.
FAU - Zhou, Yifu
AU  - Zhou Y
AD  - Cardiothoracic Surgery Research Program, National Heart, Lung and Blood 
      Institute, National Institutes of Health, Bethesda, Maryland.
FAU - Robey, Pamela G
AU  - Robey PG
AD  - NIH Bone Marrow Stromal Cell Transplantation Center, National Institute of Dental 
      and Craniofacial Research, National Institutes of Health, Bethesda, Maryland.
FAU - Stroncek, David F
AU  - Stroncek DF
AD  - Department of Transfusion Medicine, Clinical Center, National Institutes of 
      Health, Bethesda, Maryland.
FAU - Arai, Andrew E
AU  - Arai AE
AD  - Advanced Cardiovascular Imaging Group, National Heart, Lung and Blood Institute, 
      National Institutes of Health, Bethesda, Maryland.
FAU - Sachdev, Vandana
AU  - Sachdev V
AD  - Echocardiography Laboratory, National Heart, Lung and Blood Institute, National 
      Institutes of Health, Bethesda, Maryland.
FAU - Horvath, Keith A
AU  - Horvath KA
AD  - Cardiothoracic Surgery Research Program, National Heart, Lung and Blood 
      Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: 
      khorvath@aamc.org.
LA  - eng
GR  - HHSN268201300001C/HB/NHLBI NIH HHS/United States
GR  - U01 CA224766/CA/NCI NIH HHS/United States
GR  - ZIB DE000730/ImNIH/Intramural NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20190914
PL  - Netherlands
TA  - Ann Thorac Surg
JT  - The Annals of thoracic surgery
JID - 15030100R
SB  - IM
CIN - Ann Thorac Surg. 2020 Dec;110(6):2104. PMID: 32497645
CIN - Ann Thorac Surg. 2020 Dec;110(6):2104-2105. PMID: 32504595
MH  - Coronary Angiography
MH  - Feasibility Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections
MH  - Male
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Mesenchymal Stem Cells/*cytology
MH  - Middle Aged
MH  - Myocardial Contraction/*physiology
MH  - Myocardial Ischemia/diagnosis/physiopathology/*therapy
MH  - Myocardial Revascularization/*methods
MH  - Myocardium
MH  - Preoperative Care/*methods
MH  - Quality of Life
MH  - Ventricular Function, Left/*physiology
PMC - PMC8045460
MID - NIHMS1544312
EDAT- 2019/09/19 06:00
MHDA- 2020/05/28 06:00
PMCR- 2021/04/14
CRDT- 2019/09/19 06:00
PHST- 2019/01/21 00:00 [received]
PHST- 2019/07/04 00:00 [revised]
PHST- 2019/07/29 00:00 [accepted]
PHST- 2019/09/19 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
PHST- 2019/09/19 06:00 [entrez]
PHST- 2021/04/14 00:00 [pmc-release]
AID - S0003-4975(19)31394-3 [pii]
AID - 10.1016/j.athoracsur.2019.07.093 [doi]
PST - ppublish
SO  - Ann Thorac Surg. 2020 Apr;109(4):1142-1149. doi: 
      10.1016/j.athoracsur.2019.07.093. Epub 2019 Sep 14.